111 Total Long Term Liabilities 2018-2024 | YI
111 total long term liabilities from 2018 to 2024. Total long term liabilities can be defined as the sum of all non-current liabilities.
| 111 Annual Total Long Term Liabilities (Millions of US $) |
|
|---|---|
| 2023 | $132 |
| 2022 | $168 |
| 2021 | $183 |
| 2020 | $152 |
| 2019 | $9 |
| 2018 | $1 |
| 2017 | $228 |
| 111 Quarterly Total Long Term Liabilities (Millions of US $) |
|
|---|---|
| 2024-06-30 | $128 |
| 2024-03-31 | $131 |
| 2023-12-31 | $132 |
| 2023-09-30 | $123 |
| 2023-06-30 | $162 |
| 2023-03-31 | $168 |
| 2022-12-31 | $168 |
| 2022-09-30 | $163 |
| 2022-06-30 | $173 |
| 2022-03-31 | $184 |
| 2021-12-31 | $183 |
| 2021-09-30 | $178 |
| 2021-06-30 | $164 |
| 2021-03-31 | $159 |
| 2020-12-31 | $152 |
| 2020-09-30 | $70 |
| 2020-06-30 | $8 |
| 2020-03-31 | $9 |
| 2019-12-31 | $9 |
| 2019-09-30 | $9 |
| 2019-06-30 | $7 |
| 2019-03-31 | $7 |
| 2018-09-30 | |
| 2017-12-31 | $228 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Information Systems | $0.053B | $2.105B |
| 111, Inc. operates as a digital and mobile healthcare platform. The Company offers pharmacy distribution, medical consultancy, e-prescription and other services. 111, Inc. is headquartered in Shanghai, China. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tempus AI (TEM) | United States | $8.497B | 0.00 |
| Inspire Medical Systems (INSP) | United States | $5.276B | 164.53 |
| Hims & Hers Health (HIMS) | United States | $5.141B | 130.72 |
| Privia Health (PRVA) | United States | $2.533B | 211.10 |
| Enovis (ENOV) | United States | $2.529B | 17.15 |
| IRhythm Technologies (IRTC) | United States | $2.362B | 0.00 |
| Azenta (AZTA) | United States | $2.001B | 99.78 |
| Omnicell (OMCL) | United States | $1.964B | 64.26 |
| Clover Health Investments (CLOV) | United States | $1.644B | 0.00 |
| 10x Genomics (TXG) | United States | $1.643B | 0.00 |
| Schrodinger (SDGR) | United States | $1.378B | 0.00 |
| Phreesia (PHR) | United States | $1.072B | 0.00 |
| Butterfly Network (BFLY) | United States | $0.650B | 0.00 |
| Standard BioTools (LAB) | United States | $0.562B | 0.00 |
| Talkspace (TALK) | United States | $0.522B | 0.00 |
| Fulgent Genetics (FLGT) | United States | $0.520B | 0.00 |
| Definitive Healthcare (DH) | United States | $0.483B | 83.60 |
| Health Catalyst (HCAT) | United States | $0.459B | 0.00 |
| TruBridge (TBRG) | United States | $0.244B | 71.22 |
| Pulmonx (LUNG) | United States | $0.237B | 0.00 |
| SOPHiA GENETICS SA (SOPH) | Switzerland | $0.214B | 0.00 |
| American Well (AMWL) | United States | $0.122B | 0.00 |
| EUDA Health Holdings (EUDA) | Singapore | $0.107B | 0.00 |
| P3 Health Partners (PIII) | United States | $0.075B | 0.00 |
| HeartBeam (BEAT) | United States | $0.067B | 0.00 |
| CareCloud (CCLD) | United States | $0.046B | 0.00 |
| Zepp Health (ZEPP) | China | $0.040B | 0.00 |
| SHL Telemedicine (SHLT) | Israel | $0.040B | 0.00 |
| Outset Medical (OM) | United States | $0.039B | 0.00 |
| Movano (MOVE) | United States | $0.020B | 0.00 |
| Bullfrog AI Holdings (BFRG) | United States | $0.019B | 0.00 |
| Streamline Health Solutions (STRM) | United States | $0.014B | 0.00 |
| Strata Skin Sciences (SSKN) | United States | $0.013B | 0.00 |
| ImmunoPrecise Antibodies (IPA) | Canada | $0.012B | 0.00 |
| MSP Recovery (LIFW) | United States | $0.010B | 0.00 |
| Precipio (PRPO) | United States | $0.009B | 0.00 |
| Healthcare Triangle (HCTI) | United States | $0.006B | 0.00 |
| Mobile-health Network Solutions (MNDR) | Singapore | $0.006B | 0.00 |
| Predictive Oncology (POAI) | United States | $0.004B | 0.00 |
| Syra Health (SYRA) | United States | $0.004B | 0.00 |
| HeartSciences (HSCS) | United States | $0.002B | 0.00 |
| Zhongchao (ZCMD) | China | $0.002B | 0.00 |
| Tivic Health Systems (TIVC) | United States | $0.002B | 0.00 |
| Future Health ESG (FHLT) | United States | $0.000B | 0.00 |
| MDxHealth SA (MDXH) | Belgium | $0.000B | 0.00 |
| Nyxoah SA (NYXH) | Belgium | $0.000B | 0.00 |